05:46 PM EST, 11/11/2025 (MT Newswires) -- Profound Medical ( PROF ) said late Tuesday it signed a distribution and supply agreement for its Tulsa-Pro and Sonalleve technologies in Saudi Arabia with Al Faisaliah Medical Systems.

The company said all required regulatory approvals to import and sell the two ablative therapies in the country are already in place.

Profound said the US commercialization of Tulsa-Pro, used in the treatment of prostate disease, remains its main priority. Sonalleve, used primarily for treating uterine fibroids, is sold as a one-time capital system and has seen growing commercial interest, particularly outside the US.

Shares of Profound Medical ( PROF ) rose over 4% in after-hours activity.